Table 2.
Dup15q syndrome participant characteristics (longitudinal study)
| Participant | Duplication type | Visit 1 Age (months) | Visit 2 Age (months) | Epilepsy (active) | Medications |
|---|---|---|---|---|---|
| P1 | Isodicentric | 57 | 72 | No | N/A |
| P2 | Isodicentric | 18 | 28 | Yes (at second visit) | Vigabatrin (at second visit) |
| P3 | Interstitial | 51 | 78 | No | N/A |
| P4 | Isodicentric | 110 | 134 | No | N/A |
| P5 | Isodicentric | 84 | 100 | Yes (at both visits) | Carbamazepine; levetiracetam (unchanged at both visits) |
| P6 | Interstitial | 48 | 72 | No | N/A |
| P7 | Isodicentric | 29 | 53 | Yes (at second visit) | Lamotrigine (at second visit) |
| P8 | Isodicentric | 38 | 61 | Yes (at both visits) | Valproate, clobazam, lacosamide, perampanel (unchanged at both visits) |
| P9 | Interstitial | 44 | 68 | No | N/A |
| P10 | Interstitial | 161 | 185 | No | N/A |
N/A not available. Dosages were not available for all the medications listed, hence not included in the table